34.55
전일 마감가:
$34.09
열려 있는:
$34.19
하루 거래량:
730.59K
Relative Volume:
1.55
시가총액:
$1.72B
수익:
$499.95M
순이익/손실:
$-36.36M
주가수익비율:
-44.87
EPS:
-0.77
순현금흐름:
$24.22M
1주 성능:
-7.96%
1개월 성능:
-1.99%
6개월 성능:
+15.51%
1년 성능:
+4.13%
Atricure Inc Stock (ATRC) Company Profile
명칭
Atricure Inc
전화
513-755-4100
주소
7555 INNOVATION WAY, MASON, OH
ATRC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ATRC
Atricure Inc
|
34.55 | 1.69B | 499.95M | -36.36M | 24.22M | -0.77 |
|
ISRG
Intuitive Surgical Inc
|
534.28 | 187.89B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
178.71 | 51.42B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
ALC
Alcon Inc
|
73.89 | 36.71B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
RMD
Resmed Inc
|
246.88 | 36.82B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
WST
West Pharmaceutical Services Inc
|
282.07 | 20.04B | 2.96B | 487.70M | 344.00M | 6.6758 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-17 | 재개 | JP Morgan | Overweight |
| 2024-04-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-23 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-29 | 개시 | UBS | Buy |
| 2021-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-12-18 | 재확인 | Needham | Buy |
| 2020-11-06 | 재확인 | Needham | Buy |
| 2020-04-07 | 개시 | Oppenheimer | Outperform |
| 2020-02-06 | 개시 | BTIG Research | Buy |
| 2020-01-24 | 재확인 | Needham | Buy |
| 2019-08-13 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | 개시 | JP Morgan | Overweight |
| 2018-10-04 | 재확인 | Needham | Buy |
| 2018-08-02 | 재확인 | Needham | Buy |
| 2018-08-02 | 재확인 | Stifel | Buy |
| 2018-06-18 | 재확인 | Needham | Buy |
| 2018-04-27 | 재확인 | Needham | Buy |
| 2018-01-16 | 재확인 | Needham | Buy |
| 2017-11-02 | 재확인 | Needham | Buy |
| 2017-07-28 | 재확인 | Needham | Buy |
| 2017-05-30 | 재개 | Piper Jaffray | Overweight |
| 2016-06-30 | 재개 | JMP Securities | Mkt Outperform |
| 2015-10-28 | 재확인 | Needham | Buy |
| 2015-10-06 | 재확인 | Canaccord Genuity | Buy |
| 2015-10-06 | 재확인 | Needham | Buy |
모두보기
Atricure Inc 주식(ATRC)의 최신 뉴스
AtriCure Inc. stock trendline breakdownTrade Performance Summary & Precise Swing Trade Alerts - newser.com
Does AtriCure Inc. qualify in momentum factor screeningTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Exit strategy if you’re trapped in AtriCure Inc.Bull Run & Stepwise Swing Trade Plans - newser.com
Why AtriCure Inc. stock is recommended by analystsJuly 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
Intraday pattern recognizer results for AtriCure Inc.Weekly Profit Analysis & Stock Portfolio Risk Management - newser.com
How sustainable is AtriCure Inc. stock dividend payoutJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
AtriCure, Inc. (ATRC) Analyst insights, Price targets and Recommendations - Yahoo! Finance Australia
AtriCure raises 2025 revenue outlook to $532M–$534M as product launches propel double-digit growth - MSN
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Is AtriCure Inc. stock overvalued by current metricsMarket Performance Recap & Growth Oriented Trading Recommendations - newser.com
AtriCure’s BoxX-NoAF Trial: A Step Forward in Cardiac Surgery Innovation - MSN
AtriCure’s Earnings Call Highlights Robust Growth and Innovation - The Globe and Mail
AtriCure, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:ATRC) 2025-10-31 - Seeking Alpha
AtriCure’s HEAL-IST IDE Trial: A Promising Step in Treating Inappropriate Sinus Tachycardia - MSN
AtriCure (NASDAQ:ATRC) Sees Large Volume Increase on Strong Earnings - MarketBeat
Atricure (ATRC) Gets a Buy from Canaccord Genuity - The Globe and Mail
AtriCure (ATRC) Margin Miss Challenges Hopes for Near-Term Profitability Despite Strong Growth Forecasts - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
AtriCure Inc. stock trend forecastInsider Selling & Smart Allocation Stock Tips - newser.com
Analyzing drawdowns of AtriCure Inc. with statistical toolsMarket Performance Summary & Capital Protection Trade Alerts - newser.com
Why AtriCure Inc. stock is seen as undervaluedRate Cut & AI Optimized Trading Strategy Guides - newser.com
Canaccord Genuity raises AtriCure stock price target to $64 on strong Q3 results - Investing.com Nigeria
AtriCure stock maintains Buy rating at Needham following strong Q3 results - Investing.com Australia
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial - MedTech Intelligence
AtriCure stock maintains Buy rating at Needham following strong Q3 results By Investing.com - Investing.com South Africa
AtriCure stock rises as Citizens reiterates Market Outperform rating after strong Q3 - Investing.com UK
Is AtriCure Inc. stock trading near support levels2025 Top Decliners & AI Driven Stock Reports - newser.com
AtriCure, Inc. Reports Strong Q3 2025 Results - The Globe and Mail
Decoding AtriCure Inc (ATRC): A Strategic SWOT Insight - GuruFocus
AtriCure (NASDAQ:ATRC) Updates FY 2025 Earnings Guidance - MarketBeat
Canaccord Genuity Maintains AtriCure (ATRC) Buy Recommendation - Nasdaq
AtriCure (NASDAQ:ATRC) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
AtriCure Inc (ATRC) Q3 2025 Earnings Call Highlights: Strong Rev - GuruFocus
AtriCure (ATRC) Q3 2025 Earnings Call Transcript - The Globe and Mail
AtriCure, Inc. SEC 10-Q Report - TradingView
[10-Q] AtriCure, Inc. Quarterly Earnings Report | ATRC SEC FilingForm 10-Q - Stock Titan
AtriCure (ATRC) Target Price Raised by Canaccord Genuity | ATRC Stock News - GuruFocus
AtriCure’s TRAC-AF Registry: A Closer Look at Ongoing Clinical Study - MSN
AtriCure Q3 2025 Earnings Call Transcript - MarketBeat
AtriCure earnings beat by $0.10, revenue topped estimates - Investing.com Canada
AtriCure: Q3 Earnings Snapshot - Stamford Advocate
Transcript : AtriCure, Inc., Q3 2025 Earnings Call, Oct 29, 2025 - MarketScreener
AtriCure (ATRC) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025 - BioSpace
Atricure Inc (ATRC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):